查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613312

樹突細胞癌疫苗市場：依癌症類型、最終用途分類 - 2025-2030 年全球預測

Dendritic Cell Cancer Vaccine Market by Cancer Type (Breast Cancer, Liver Cancer, Lung Cancer), End-use (Hospitals, Research Institutes, Specialty Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年樹突狀細胞癌疫苗市場規模為35,006萬美元，預計2024年將達3,9,259萬美元，複合年成長率為13.05%，2030年將達8,2649萬美元，預計將達1000萬美元。

樹突細胞癌症疫苗市場圍繞著腫瘤學一個有前途的領域：旨在利用樹突狀細胞刺激免疫系統攻擊癌細胞的疫苗。這些疫苗代表了針對多種癌症類型的癌症免疫療法的創新方法，包括黑色素瘤、前列腺癌和神經膠母細胞瘤。這些疫苗的需求源於對比化療和放射線治療等傳統治療方法副作用較少的更有效的癌症療法的需求。最終用途涵蓋各種癌症階段和類型，反映了世界各地腫瘤學和先進臨床研究設施的廣泛最終用途。推動市場開拓的主要因素是生物技術的進步、癌症發生率的增加以及醫療機構研發投資的增加。生物技術公司和研發機構之間的合作促進創新產品開發並為客製化癌症疫苗鋪平道路，這是一個巨大的商機。鼓勵公司專注於個人化醫療的創新，並探索與人工智慧技術提供者的合作夥伴關係，以加強疫苗開發流程。另一方面，市場開拓面臨的挑戰包括開發成本高、監管條件嚴格以及世界某些地區的認知度低。此外，臨床試驗的複雜性和患者反應的可變性構成了主要障礙。然而，由於醫療基礎設施的擴大和癌症發病率的上升，新興市場的潛力開拓。創新研究領域包括透過聯合治療和在疫苗配方中使用奈米技術來提高疫苗功效。該市場本質上充滿活力且快速發展，為投資尖端研究、策略聯盟和高效供應鏈管理的公司提供了巨大的成長潛力。透過抓住這些機會並克服現有障礙，公司可以有效地為推進全球癌症治療方法和改善患者治療結果做出貢獻。

主要市場統計
基準年[2023] 35006萬美元
預計年份 [2024] 3.9259 億美元
預測年份 [2030] 8.2649億美元
複合年成長率（%） 13.05%

市場動態：快速發展的樹突狀細胞癌疫苗市場的關鍵市場洞察

樹突狀細胞癌疫苗市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球癌症患者數量增加
    • 免疫療法和個人化醫療的持續進步
  • 市場限制因素
    • 樹突細胞疫苗技術開發成本高
  • 市場機會
    • 樹突細胞生物學和疫苗技術領域的研發不斷增加
    • 加速癌症治療開發的支持性法規結構
  • 市場挑戰
    • 對樹突細胞疫苗技術的好處認知不足

波特五力：駕馭樹突細胞癌疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解樹突狀細胞癌疫苗市場的外部影響

外部宏觀環境因素在塑造樹突狀細胞癌疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解樹突細胞癌疫苗市場的競爭狀況

對樹突狀細胞癌疫苗市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣樹突狀細胞癌疫苗市場供應商績效評估

FPNV定位矩陣是評估樹突狀細胞癌疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了樹突狀細胞癌疫苗市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對樹突狀細胞癌疫苗市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球癌症發生率增加
      • 免疫療法和個人化醫療的持續進步
    • 抑制因素
      • 樹突細胞疫苗技術開發成本高
    • 機會
      • 加大樹突細胞生物學和疫苗技術領域的研發力度
      • 加速癌症治療開發的支持性法規結構
    • 任務
      • 對樹突細胞疫苗技術優勢的認知有限
  • 市場區隔分析
    • 癌症類型：特異性針對癌細胞的前列腺癌樹突狀細胞癌疫苗的潛力不斷成長
    • 最終用途：在醫院綜合護理設施中增加樹突狀細胞癌疫苗的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章樹突細胞癌疫苗市場：依癌症類型

  • 乳癌
  • 肝癌
  • 肺癌
  • 卵巢癌
  • 胰臟癌
  • 攝護腺癌

第7章樹突細胞癌疫苗市場：依最終用途分類

  • 醫院
  • 調查機構
  • 專科診所

第8章美洲樹突細胞癌疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區樹突細胞癌疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲樹突細胞癌疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • BioNTech 開始基於 mRNA 的個人化新抗原特異性免疫療法的 2 期試驗，擴大後期臨床腫瘤學產品組合
  • 戰略分析和建議

公司名單

  • Aduro Biotech
  • APAC Biotech
  • Argos Therapeutics
  • Batavia Biosciences BV
  • Creative Biolabs
  • Dendreon Pharmaceuticals
  • GSK PLC
  • ImmunoCellular Therapeutics
  • JW CreaGene
  • Northwest Biotherapeutics
  • Northwest Biotherapeutics, Inc.
  • Nouscom
Product Code: MRR-351BAD503B28

The Dendritic Cell Cancer Vaccine Market was valued at USD 350.06 million in 2023, expected to reach USD 392.59 million in 2024, and is projected to grow at a CAGR of 13.05%, to USD 826.49 million by 2030.

The Dendritic Cell Cancer Vaccine market revolves around a promising field in oncology where vaccines are designed to use dendritic cells to stimulate the immune system to attack cancer cells. These vaccines represent an innovative approach to cancer immunotherapy, targeting various cancer types including melanoma, prostate, and glioblastoma. The necessity of these vaccines arises from the need for more effective cancer treatments with fewer side effects compared to traditional therapies like chemotherapy and radiation. Applications span across treating different cancer stages and types, reflecting a broad end-use scope in oncology departments and advanced clinical research facilities globally. Market growth is primarily fueled by advancements in biotechnology, increasing prevalence of cancer, and growing investment in research and development by healthcare institutions. A significant opportunity arises from collaborations between biotech companies and research institutions, fostering innovative product development and paving the way for customized cancer vaccines. Companies are encouraged to focus on innovation around personalized medicine and to explore partnerships with AI technology providers to enhance vaccine development processes. Conversely, market growth is challenged by high development costs, stringent regulatory landscapes, and limited awareness in some parts of the world. Moreover, the complexity of clinical trials and variability in patient response also pose significant hurdles. However, emerging markets hold untapped potential due to their expanding healthcare infrastructure and increasing cancer prevalence. Innovative research areas include enhancing vaccine efficacy through combination therapies and the use of nanotechnology in vaccine formulation. The market, inherently dynamic and rapidly evolving, presents substantial growth possibilities for businesses that invest in cutting-edge research, strategic collaborations, and efficient supply chain management. By addressing these opportunities and overcoming the existing barriers, companies can effectively contribute to advancing cancer treatment modalities and improving patient outcomes globally.

KEY MARKET STATISTICS
Base Year [2023] USD 350.06 million
Estimated Year [2024] USD 392.59 million
Forecast Year [2030] USD 826.49 million
CAGR (%) 13.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dendritic Cell Cancer Vaccine Market

The Dendritic Cell Cancer Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer cases worldwide
    • Continuous advancements in immunotherapy and personalized medicines
  • Market Restraints
    • High cost of development of dendritic cell vaccine technology
  • Market Opportunities
    • Rising research and development efforts in the field of dendritic cell biology and vaccine technology
    • Supportive regulatory frameworks for accelerating the development of cancer therapies
  • Market Challenges
    • Limited awareness associated with benefits of dendritic cell vaccine technology

Porter's Five Forces: A Strategic Tool for Navigating the Dendritic Cell Cancer Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dendritic Cell Cancer Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dendritic Cell Cancer Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dendritic Cell Cancer Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dendritic Cell Cancer Vaccine Market

A detailed market share analysis in the Dendritic Cell Cancer Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dendritic Cell Cancer Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dendritic Cell Cancer Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dendritic Cell Cancer Vaccine Market

A strategic analysis of the Dendritic Cell Cancer Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dendritic Cell Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include Aduro Biotech, APAC Biotech, Argos Therapeutics, Batavia Biosciences B.V., Creative Biolabs, Dendreon Pharmaceuticals, GSK PLC, ImmunoCellular Therapeutics, JW CreaGene, Northwest Biotherapeutics, Northwest Biotherapeutics, Inc., and Nouscom.

Market Segmentation & Coverage

This research report categorizes the Dendritic Cell Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Cancer Type, market is studied across Breast Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Prostate Cancer.
  • Based on End-use, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer cases worldwide
      • 5.1.1.2. Continuous advancements in immunotherapy and personalized medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of dendritic cell vaccine technology
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising research and development efforts in the field of dendritic cell biology and vaccine technology
      • 5.1.3.2. Supportive regulatory frameworks for accelerating the development of cancer therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness associated with benefits of dendritic cell vaccine technology
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Cancer Type: Rising potential of dendritic cell cancer vaccine for prostate cancer that can specifically target cancer cells
    • 5.2.2. End-use: Rising usage of dendritic cell cancer vaccine across hospitals due to their comprehensive care facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dendritic Cell Cancer Vaccine Market, by Cancer Type

  • 6.1. Introduction
  • 6.2. Breast Cancer
  • 6.3. Liver Cancer
  • 6.4. Lung Cancer
  • 6.5. Ovarian Cancer
  • 6.6. Pancreatic Cancer
  • 6.7. Prostate Cancer

7. Dendritic Cell Cancer Vaccine Market, by End-use

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Research Institutes
  • 7.4. Specialty Clinics

8. Americas Dendritic Cell Cancer Vaccine Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Dendritic Cell Cancer Vaccine Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Dendritic Cell Cancer Vaccine Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aduro Biotech
  • 2. APAC Biotech
  • 3. Argos Therapeutics
  • 4. Batavia Biosciences B.V.
  • 5. Creative Biolabs
  • 6. Dendreon Pharmaceuticals
  • 7. GSK PLC
  • 8. ImmunoCellular Therapeutics
  • 9. JW CreaGene
  • 10. Northwest Biotherapeutics
  • 11. Northwest Biotherapeutics, Inc.
  • 12. Nouscom

LIST OF FIGURES

  • FIGURE 1. DENDRITIC CELL CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DENDRITIC CELL CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DENDRITIC CELL CANCER VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM DENDRITIC CELL CANCER VACCINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. DENDRITIC CELL CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. DENDRITIC CELL CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023